Patents by Inventor Lieven Meerpoel

Lieven Meerpoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12145961
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: November 19, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E Denmark
  • Patent number: 11993614
    Abstract: The present invention relates to novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 28, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelius Bernardus Catharina Parade, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Publication number: 20240124493
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 18, 2024
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelius Bernardus Catharina Parade, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Patent number: 11883367
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: January 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Publication number: 20230330127
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (1) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 21, 2023
    Publication date: October 19, 2023
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Amodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelius Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Publication number: 20230303612
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 28, 2023
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E. Denmark
  • Patent number: 11702441
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: July 18, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E. Denmark
  • Publication number: 20230071711
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 9, 2022
    Publication date: March 9, 2023
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Amodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Publication number: 20220275018
    Abstract: The present invention relates to novel spirobicyclic intermediates useful in the synthesis of spirobicyclic nucleoside analogues.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 1, 2022
    Inventors: Jonas VERHOEVEN, Marta BRAMBILLA, Nagaraju CHINTA, Jan Julien A. HULLAERT, Lucile Marguerite JOUFFROY, Lieven MEERPOEL, Zeina NEOUCHY, Johannes Wilhelmus John F. THURING, Guido Alfons F. VERNIEST, Johan Maurits WINNE
  • Publication number: 20220135544
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Patent number: 11318157
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Patent number: 11267804
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Patent number: 11236084
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: February 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Calum Macleod, Samuel Edward Mann, Janusz Jozef Kulagowski, Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel
  • Publication number: 20210380627
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: June 10, 2021
    Publication date: December 9, 2021
    Inventors: Jonas Verhoeven, Guido Alfons F. Verniest, Johannes Wilhelmus John F. Thuring, Tongfei Wu, Vineet Pande, Lieven Meerpoel, Dirk Brehmer, Weimei Sun, Scott E. Denmark
  • Publication number: 20210371433
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: July 16, 2021
    Publication date: December 2, 2021
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Jason Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelius Bernardus Catharina Parade, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye
  • Patent number: 11186589
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11180487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Patent number: 11136311
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • Patent number: 11098062
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Edward Charles Lawson, Lieven Meerpoel, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Weimei Sun, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye